Idorsia Ltd (IDRSF)
OTCMKTS
· Delayed Price · Currency is USD
3.015
+0.215 (7.68%)
At close: Jul 10, 2025
Idorsia Revenue
Idorsia had revenue of 58.88M CHF in the quarter ending March 31, 2025, with 485.38% growth. This brings the company's revenue in the last twelve months to 161.33M, up 14.08% year-over-year. In the year 2024, Idorsia had annual revenue of 112.51M, down -26.17%.
Revenue (ttm)
161.33M CHF
Revenue Growth
+14.08%
P/S Ratio
3.29
Revenue / Employee
248.20K CHF
Employees
650
Market Cap
600.01M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 112.51M | -39.88M | -26.17% |
Dec 31, 2023 | 152.39M | 55.28M | 56.93% |
Dec 31, 2022 | 97.10M | 61.75M | 174.70% |
Dec 31, 2021 | 35.35M | -36.41M | -50.74% |
Dec 31, 2020 | 71.76M | 47.94M | 201.26% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
American Oncology Network | 1.76B |
Northwest Biotherapeutics | 1.47M |
Silence Therapeutics | 27.70M |
Idorsia News
- 13 days ago - A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans - GlobeNewsWire
- 18 days ago - Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds - GlobeNewsWire
- 4 weeks ago - Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia - GlobeNewsWire
- 5 weeks ago - Idorsia publishes invitations to bondholder meetings - GlobeNewsWire
- 6 weeks ago - Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025 - GlobeNewsWire
- 7 weeks ago - New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia's path to profitability - GlobeNewsWire
- 2 months ago - Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders - GlobeNewsWire
- 3 months ago - Idorsia publishes its Annual Report 2024 - GlobeNewsWire